We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-7.15%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$171M
AUM Growth
-$23M
Cap. Flow
+$1.07M
Cap. Flow %
0.63%
Top 10 Hldgs %
90.76%
Holding
44
New
4
Increased
4
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$1.3M
2
AXGN icon
Axogen
AXGN
+$826K
3
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$732K
4
VYGR icon
Voyager Therapeutics
VYGR
+$326K
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$297K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.92M
2
MRK icon
Merck
MRK
+$640K
3
PRTA icon
Prothena Corp
PRTA
+$235K

Sector Composition

Rank Sector Weight
1 Healthcare 95.93%
2 Energy 2.75%
3 Industrials 0.47%
4 Consumer Staples 0.28%
5 Consumer Discretionary 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMTA
26
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$418K 0.25%
22,000
– –
DRNA
27
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$406K 0.24%
45,000
– –
CLVS
28
DELISTED
Clovis Oncology, Inc.
CLVS
$340K 0.2%
5,000
– –
BIIB icon
29
Biogen
BIIB
$30B
$319K 0.19%
1,000
– –
QTNT
30
DELISTED
Quotient Limited Ordinary Shares
QTNT
$296K 0.17%
1,493
– –
CELGZ
31
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$283K 0.17%
291,877
– –
XNCR icon
32
Xencor
XNCR
$1.46B
$270K 0.16%
12,300
– –
ARRY
33
DELISTED
Array Biopharma Inc
ARRY
$256K 0.15%
+20,000
New +$227K
ICPT
34
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$251K 0.15%
4,300
– –
GNMX
35
DELISTED
Aevi Genomic Medicine Inc
GNMX
$154K 0.09%
128,000
– –
FOLD
36
DELISTED
Amicus Therapeutics
FOLD
$144K 0.08%
10,000
– –
WKHS icon
37
Workhorse Group
WKHS
$29.6M
$128K 0.08%
17
– –
OMED
38
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$118K 0.07%
28,689
– –
CYTK icon
39
Cytokinetics
CYTK
$11.1B
$82K 0.05%
10,000
– –
GNCA
40
DELISTED
Genocea Biosciences, Inc.
GNCA
$45K 0.03%
4,875
– –
ANTH
41
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$23K 0.01%
+15,378
New +$26.5K
MRK icon
42
Merck
MRK
$323B
– –
-10,480
Closed -$640K
PRTA icon
43
Prothena Corp
PRTA
$442M
– –
-3,632
Closed -$235K
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM

Birchview Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Birchview Capital held 44 positions worth $171M, down 12% from $194M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Birchview Capital's Q4 2017 filing shows 4 new, 4 increased, 1 reduced and 2 closed positions. Its largest new stake was Soleno Therapeutics: 45,229 shares worth $1.03M. The largest sale was Celgene Corp, an estimated $1.92M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Energy and Industrials.

  • Birchview Capital's largest Q4 2017 buy was Soleno Therapeutics: 45,229 shares worth $1.03M.
  • Birchview Capital added most to Oxford Immunotec Global PLC Ordinary Shares in Q4 2017, an estimated $732K increase.
  • Birchview Capital's biggest Q4 2017 reduction was Celgene Corp, cutting an estimated $1.92M.
  • Birchview Capital fully exited Merck in Q4 2017, selling an estimated $640K.
  • Birchview Capital's ten largest holdings make up 91% of its $171M portfolio in Q4 2017.
  • Birchview Capital opened 4 new positions and closed 2 in Q4 2017.
  • Birchview Capital's portfolio value fell 12% quarter-over-quarter to $171M.

Based on Birchview Capital's 13F filing for Q4 2017, filed 2 Feb 2018.